Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Aripiprazole Sandoz (aripiprazole) — Sandoz GmbH
Authorised new aripiprazole product (Sandoz) for schizophrenia and bipolar disorder.
-
EMA approval · 2026-07-29EMA Authorised: Rxulti (brexpiprazole) — Otsuka Pharmaceutical Netherlands B.V.
Brexpiprazole (Rxulti) has been authorised in the EU for schizophrenia, with Otsuka Pharmaceutical Netherlands B.V. as the marketing authori…
-
EMA approval · 2026-07-10EMA Authorised: Olazax (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Olazax, containing olanzapine, has been authorised for schizophrenia and bipolar disorder in the EU.
-
EMA approval · 2026-07-01EMA Authorised: Zypadhera (olanzapine pamoate) — CHEPLAPHARM Registration GmbH
The EMA has authorised Zypadhera (olanzapine pamoate) for schizophrenia, with CHEPLAPHARM Registration GmbH as the marketing authorisation h…
-
EMA approval · 2026-06-10EMA Authorised: Byannli (previously Paliperidone Janssen-Cilag International) (paliperidone palmitate) — Janssen-Cilag International N.V.
The EMA has authorised Byannli (paliperidone palmitate) from Janssen-Cilag International for schizophrenia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-06-03EMA Authorised: Xeplion (paliperidone palmitate) — Janssen-Cilag International N.V.
EMA authorises Xeplion (paliperidone palmitate) for schizophrenia, with Janssen-Cilag International N.V. as the MAH.
-
FDA approval · 2026-04-22FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for quetiapine fumarate from Accord Healthcare Inc., updating the product's labeling and/or indicati…
-
FDA approval · 2026-04-13FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's supplemental application for lurasidone hydrochloride, signifying an update to the product's …
-
EMA approval · 2026-04-13EMA Authorised: Aripiprazole Sandoz (aripiprazole) — Sandoz GmbH
The European Medicines Agency authorised Aripiprazole Sandoz (aripiprazole) by Sandoz GmbH for treating schizophrenia and bipolar disorder.
-
EMA approval · 2026-04-08EMA Authorised: Aripiprazole Zentiva (aripiprazole) — Zentiva, k.s.
The EMA has authorised Aripiprazole Zentiva (aripiprazole) for the treatment of schizophrenia and bipolar disorder. The marketing authorizat…
-
FDA approval · 2026-03-27FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for haloperidol decanoate from NorthStar RxLLC under ANDA216730.
-
FDA approval · 2026-03-27FDA Approved: ASENAPINE — Supplemental Application (Sigmapharm Laboratories, LLC)
FDA approved a supplemental application for asenapine from Sigmapharm Laboratories, allowing a generic version of asenapine to be marketed. …
-
EMA approval · 2026-03-23EMA Authorised: Rxulti (brexpiprazole) — Otsuka Pharmaceutical Netherlands B.V.
The European Medicines Agency authorised Rxulti (brexpiprazole) for schizophrenia in the European Union. The marketing authorisation holder …
-
FDA approval · 2026-03-05FDA Approved: OLANZAPINE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Glenmark's original application for a generic olanzapine product.
-
EMA approval · 2026-02-27EMA Authorised: Zyprexa (olanzapine) — CHEPLAPHARM Registration GmbH
The EMA authorised Zyprexa (olanzapine) for schizophrenia and bipolar disorder under CHEPLAPHARM Registration GmbH as the marketing authoris…
-
FDA approval · 2026-02-18FDA Approved: ARIPIPRAZOLE — Original Application (Aurobindo Pharma Limited)
FDA approved the original ANDA for aripiprazole from Aurobindo Pharma Limited, providing a generic version of the antipsychotic. The approva…
-
FDA approval · 2026-02-09FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for olanzapine from Dr. Reddy's Laboratories Inc., updating the existing approval for this product.
-
EMA approval · 2026-02-09EMA Authorised: Zypadhera (olanzapine pamoate) — CHEPLAPHARM Registration GmbH
EMA authorised Zypadhera, an olanzapine pamoate long-acting injectable, for schizophrenia, for CHEPLAPHARM Registration GmbH, decision date …
-
FDA approval · 2026-02-09FDA Approved: OLANZAPINE — Supplemental Application (Dr. Reddy's Laboratories Ltd.)
FDA approved Dr. Reddy's Laboratories' supplemental application for olanzapine, confirming the approval of a generic olanzapine product.
-
FDA approval · 2026-01-30FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) submitted by Eli Lilly and Company.
-
FDA approval · 2026-01-30FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
FDA approval · 2026-01-30FDA Approved: LYBALVI — Supplemental Application (Alkermes, Inc.)
The FDA approved a supplemental application for LYBALVI (olanzapine and samidorphan L-malate) from Alkermes, Inc., resulting in labeling cha…
-
FDA approval · 2026-01-28FDA Approved: ABILIFY MAINTENA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
FDA approved a supplemental application for ABILIFY MAINTENA (aripiprazole) from Otsuka America Pharmaceutical, indicating a modification to…
-
FDA approval · 2026-01-26FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for chlorpromazine hydrochloride, with Novadoz Pharmaceuticals LLC listed as the applicant.
-
EMA approval · 2026-01-23EMA Authorised: Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) (aripiprazole) — Mylan Pharmaceuticals Limited
EMA authorised Aripiprazole Mylan Pharma (generic aripiprazole) for schizophrenia and bipolar disorder.